A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C).

Trial Profile

A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C).

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2013

At a glance

  • Drugs ALN PCS (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 06 Oct 2013 Results published in the Lancet.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed.
    • 20 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top